This analysis examines the historical and forecast performance for Apotex in the generics pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of its sales performance.
Features and benefits
- Gain insight into Apotex's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, geography, and formulation type.
Apotex's performance through to 2016 will be shaped by new product launches after several high profile patent expiries, with steepening competitive pressures in Canada and in the US representing the most meaningful challenges the company is to face.
Your key questions answered
- Benchmark Apotex performance against key rivals in the prescription pharmaceutical sector
- Assess how successful Apotex will be in diversifying its business focus and reducing its reliance on the Canadian generics market